LAURENCE RULLEAU

Managing Partner Funds II & III

Dr. Terrisse-Rulleau brings 25 years of experience in investing in life sciences and building companies in the sector. Dr Laurence Terrisse Rulleau has been a partner with the CTI Life Sciences fund since 2014 where she has played a key role in the fund's investments but more specifically in the creation of 4 new companies in Quebec: Dalcor, a spin-off of the Montreal Heart Institute; Ilkos, a spin-off of Servier, Precithera based on innovative science and more recently Find Therapeutics, created from the granting of asset licenses from the University of Chicago and the purchase of assets of a French company. Dr. Rulleau also led the investment in Profound Medical and was an observer on the board of Directors of Visterra, a Boston-based biotechnology company acquired in August 2018 by Otsuka Pharmaceuticals. Prior to joining CTI LSF II, Laurence served as Vice-President Business Development at Univalor where she oversaw the licensing of 55 compounds to the industry and created 8 spin-off companies.

Prior to Univalor, she served as a life sciences analyst covering the Canadian life sciences sector for more than 10 years and was involved in numerous mergers and acquisitions as well as IPOs. Dr. Rulleau was ranked Canada's leading life sciences analyst by the Starmine survey (a Thomson Reuters company) and the first independent analyst by the Brendon Wood poll. Laurence is also very active in the life science Canadian community and is a board director of adMare Bio Innovations (formerly the Center for Drug Research and Development or CDRD in Vancouver and the Neomed Institute in Montreal). She is also a BOD director of Dalcor, Precithera and Find Therapeutics. Additionally, she is a member of Women Innovating Together in Healthcare (WITH), Women in BIO (WIB) and Reseau-ELLE. Dr. Rulleau holds a Ph.D. from the University of Montreal executed at Montreal Clinical Research Institute.